Search the Newsreel

Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants

Vivo funds have disclosed beneficial ownership of 9.99% stakes in SAB Biotherapeutics (SABS) through various entities, including Vivo Opportunity Fund Holdings and Vivo Opportunity Cayman Fund. These stakes comprise common stock, Series B Preferred Stock, and warrants, with built-in blocking provisions ensuring that ownership …

Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS)

Commodore Capital and its related entities have disclosed an 8.95 million share beneficial ownership in SAB Biotherapeutics (SABS), representing a 9.9% stake as of June 30, 2026. This position includes common shares, shares convertible from Series B Preferred Stock, and shares from Tranche 1 …

Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G

Adage Capital Management, L.P. and related entities have reported a beneficial ownership of 8.38% in SAB Biotherapeutics, Inc. (SABS) through a Schedule 13G filing. This stake amounts to 6,405,553 shares, with shared voting and dispositive power, based on 76,464,094 outstanding shares as of May …

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $12

SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates

RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers

RA Capital Management, L.P. and affiliated entities have reported a 9.9% beneficial ownership in SAB Biotherapeutics (SABS), totaling 9,609,852 shares. This updated filing, Amendment No. 3 to Schedule 13D/A, clarifies that the change in ownership percentage is due to an increase in SAB's outstanding …

Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst

Brookline Capital Markets has increased its Q3 2026 EPS forecast for SAB Biotherapeutics, projecting a narrower loss of $0.24 per share, up from $0.25. The firm also anticipates future profitability for the company, with an estimated $0.48 EPS by FY2029. Despite varying analyst sentiments, …

What is HC Wainwright's Estimate for SABS Q3 Earnings?

H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10

H.C. Wainwright has reiterated its Buy rating on SAB Biotherapeutics (SABS.US) and maintained its price target of $10. This indicates the firm's continued confidence in the company's prospects. Investors will be watching SAB Biotherapeutics to see if it can meet these expectations.

SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates

SAB Biotherapeutics (NASDAQ:SABS) reported its quarterly earnings, meeting analyst estimates with a loss of $0.28 per share. The company is advancing its clinical programs, including accelerating enrollment for the SAFEGUARD study and planning for the Phase III PRISE-hATG study, supported by a grant. Despite …

SAB Biotherapeutics Q2 Earnings Call Highlights

SABS FY2030 EPS Boosted by Brookline Capital Markets

SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary

SAB Biotherapeutics, Inc. reported a net loss of $(22.5M) for Q2 2026, an increase from $(10.1M) in Q2 2025, with a diluted EPS of $(0.28). This was primarily due to higher R&D and G&A spending to support its registrational Phase 2b program for SAB-142. …

SAB Biotherapeutics, Inc. Financial Disclosures & SEC Filings

This page provides a comprehensive list of SAB Biotherapeutics, Inc.'s SEC filings and other key corporate documents, including earnings reports, annual reports, and corporate presentations. The documents detail the company's financial performance, operational updates, and the progress of its drug candidate, SAB-142, which targets …

SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of SAB Biotherapeutics Inc (SABS), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 30, 2026, SABS has a price momentum score of 3.93 and is trading between a …

SAB BIO schedules Aug. 6 webcast for second-quarter results

SAB Biotherapeutics (Nasdaq: SABS) will release its second-quarter 2026 financial results on the morning of Thursday, August 6, 2026. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide business updates. …

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SAB Biotherapeutics, Inc. announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:30 AM ET to discuss its second quarter 2026 financial results and provide business updates. The company is a clinical-stage biopharmaceutical firm focusing on developing a …

SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABS

The article provides a revenue breakdown for SAB Biotherapeutics, Inc. (NASDAQ: SABS). It appears to be a financial data page from TradingView, focusing on the company's financials, key segments, and performance. The content includes general financial and market information, but the specific revenue figures …

SAB Biotherapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance | TradingKey

This article provides a detailed company profile for SAB Biotherapeutics Inc (SABS), a clinical-stage biopharmaceutical company. It highlights their focus on developing human polyclonal immunotherapeutic antibodies for immunology disorders, particularly type 1 diabetes with their lead product candidate SAB-142. The report also includes financial …

SAB Biotherapeutics Inc (SABS) Institutional Confidence

This article provides details on the institutional confidence score for SAB Biotherapeutics Inc (SABS) and lists key institutional shareholders. The score remains at 7.00, with several investment firms holding significant shares. Perceptive Advisors LLC showed a notable increase in its shareholding.

SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for SAB Biotherapeutics Inc (SABS), noting its current valuation score of 6.44, which ranks it significantly lower within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 8.21, comparing it to recent highs …

SABS Technical Analysis & ETF Price Forecast

This article provides a technical analysis and price forecast for SAB Biotherapeutics Inc (SABS), indicating a "Neutral" overall technical sentiment despite some "Buy" signals from simple moving averages. The analysis highlights key momentum indicators, support and resistance levels, and various moving average interpretations for …

SAB Biotherapeutics Inc (SABS) Balance Sheet

This article provides the quarterly and annual balance sheets for SAB Biotherapeutics Inc (SABS), allowing users to analyze its financial health. It details key financial metrics including assets, liabilities, and shareholders' equity over recent fiscal quarters. The content also includes an FAQ section explaining …

SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of SAB Biotherapeutics Inc (SABS), listing major private and institutional holders, and categorizing shareholders by type such as venture capital and hedge funds. It includes historical data on institutional shareholding, showing changes in the number of institutions and …

SABS|SAB Biotherapeutics Inc|Price:3.510|Chg%:-0.070

SAB Biotherapeutics Inc. (SABS) is a clinical-stage biopharmaceutical company focused on developing human polyclonal immunotherapeutic antibodies for immunology disorders, primarily targeting Type 1 Diabetes with its lead product candidate, SAB-142. The company, despite recent weak market performance, has strong fundamentals and its valuation is …

SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABSW

This page provides financial data and an overview for SAB Biotherapeutics, Inc. (NASDAQ: SABSW) on TradingView. It offers access to financial statements, statistics, dividends, earnings, and segment performance. The page emphasizes that no trades were made and the market is currently closed.